Plans to create and license diagnostic tools to help transplant surgeons rapidly and accurately assess the health of a lung before it is transplanted are the basis of two research and development agreements between SQI Diagnostics and Toronto’s University Health Network (UHN), in Canada. There is a significant gap between the…
News
The American Thoracic Society (ATS) has published new recommendations for home oxygen therapy to treat chronic hypoxemia (low oxygen levels in the blood) in children with chronic lung or pulmonary vascular diseases, including pulmonary hypertension (PH). The guidelines were published in the American Journal of Respiratory and Critical…
Preclinical and early clinical data showing the safety and potential therapeutic activity of rodatristat ethyl support its progression into Phase 2 trials in patients with pulmonary arterial hypertension (PAH). The most recent findings on Altavant Sciences’ lead therapy candidate were presented at the recent 13th Annual World…
Pulmonary hypertension (PH) is associated with poorer neurodevelopmental outcome and impaired growth in the first two years of life for preterm infants with bronchopulmonary dysplasia, a study shows. The study, “Developmental outcomes of preterm infants with bronchopulmonary dysplasia-associated pulmonary hypertension at 18-24 months of corrected age,” was published…
Eligible pulmonary hypertension patients could gain access to financial assistance in paying for PH therapies approved by the U.S. Food and Drug Administration (FDA) under a newly opened copay assistance program set up by The Assistance Fund (TAF). TAF is an independent charitable organization based in Florida. Started in 2009 for patients and…
United Therapeutics has now acquired worldwide rights over ralinepag, a potential oral medication under Phase 2 and 3 clinical testing for pulmonary arterial hypertension (PAH), the company announced in a press release…
A ventilator-compatible nitric oxide generator and delivery system, called AirNOvent, for patients with pulmonary hypertension and related conditions, will be made available by Circassia Pharmaceuticals to hospitals in the U.S. and China next year. This is made possible through a $32.5 million commercial license agreement signed with AIT…
High levels of cardiac troponin in the blood of pulmonary hypertension (PH) patients are associated with a poorer prognosis, according to a study. The meta-analysis study, “Serum Cardiac Troponin Elevation Predicts Mortality in Patients with Pulmonary Hypertension: A Meta‐Analysis of 8 Cohort Studies,” was published in The…
Male patients with group 3 pulmonary hypertension (PH) have worse right ventricular (RV) function compared with female patients, according to a study. Impaired RV function also was found to be associated with reduced overall survival and higher hospitalization rates linked to heart failure. The group study “Clinical Determinants and…
The prevalence of pulmonary arterial hypertension (PAH) in South Korea is comparable with that reported in other countries, according to a reassessment study of medical insurance data. The study, “Demographics, treatment trends, and survival rate in incident pulmonary artery hypertension in Korea: A nationwide study based on the…
Waiting for a lung transplant in the intensive care unit at a New York hospital in November 2017, a 21-year-old pulmonary hypertension patient named Miriam Holman sued the U.S. Department of Health and Human Services. Her lawsuit accused the department of allocating organs based on a patient’s geographic location,…
Actelion Pharmaceuticals has received a complete response letter from the U.S. Food and Drug Administration (FDA) specifying that the company needs to conduct further studies and obtain more data in order to accurately assess the use of Opsumit (macitentan) in the treatment of patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). The…
